Journal article
Association of interferon regulatory factor-4 polymorphism rs12203592 with divergent melanoma pathways
- Abstract:
-
Background
Solar elastosis and neval remnants are histologic markers characteristic of divergent melanoma pathways linked to differences in age at onset, host phenotype, and sun exposure. However, the association between these pathway markers and newly identified low-penetrance melanoma susceptibility loci remains unknown.
Methods
In the Genes, Environment and Melanoma (GEM) Study, 2103 Caucasian participants had first primary melanomas that underwent centralized pathology review. For 47 single-nucleotide polymorphisms (SNPs) previously identified as low-penetrant melanoma risk variants, we used multinomial logistic regression to compare melanoma with solar elastosis and melanoma with neval remnants simultaneously to melanoma with neither of these markers, excluding melanomas with both markers. All statistical tests were two-sided.
Results
IRF4 rs12203592 was the only SNP to pass the false discovery threshold in baseline models adjusted for age, sex, and study center. rs12203592*T was associated positively with melanoma with solar elastosis (odds ratio [OR] = 1.47, 95% confidence interval [CI] = 1.18 to 1.82) and inversely with melanoma with neval remnants (OR = 0.65, 95% CI = 0.48 to 0.87) compared with melanoma with neither marker (Pglobal = 3.78 x 10-08). Adjusting for phenotypic characteristics and total sun exposure hours did not materially affect rs12203592's associations. Distinct early- and late-onset age distributions were observed in patients with IRF4 rs12203592 [CC] and [TT] genotypes, respectively.
Conclusions
Our findings suggest a role of IRF4 rs12203592 in pathway-specific risk for melanoma development. We hypothesize that IRF4 rs12203592 could underlie in part the bimodal age distribution reported for melanoma and linked to the divergent pathways.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 301.9KB, Terms of use)
-
(Preview, Accepted manuscript, pdf, 462.7KB, Terms of use)
-
(Preview, Accepted manuscript, pdf, 167.3KB, Terms of use)
-
(Preview, Accepted manuscript, pdf, 198.8KB, Terms of use)
-
- Publisher copy:
- 10.1093/jnci/djw004
Authors
- Publisher:
- Oxford University Press
- Journal:
- Journal of the National Cancer Institute More from this journal
- Volume:
- 108
- Issue:
- 7
- Article number:
- djw004
- Publication date:
- 2016-02-08
- Acceptance date:
- 2016-01-05
- DOI:
- EISSN:
-
1460-2105
- ISSN:
-
0027-8874
- Language:
-
English
- Keywords:
- Subjects:
- Pubs id:
-
pubs:601347
- UUID:
-
uuid:21500594-6aec-4e16-9000-55c8ba692a11
- Local pid:
-
pubs:601347
- Source identifiers:
-
601347
- Deposit date:
-
2016-04-08
Terms of use
- Copyright holder:
- Gibbs et al
- Copyright date:
- 2016
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from the Oxford University Press at: DOI: https://doi.org/10.1093/jnci/djw004
If you are the owner of this record, you can report an update to it here: Report update to this record